edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
![Edwards Lifesciences logo](/files/LOGO/1099800-EW.png)
Company profile
Ticker
EW
Exchange
Website
CEO
Michael Mussallem
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign • RTI Surgical ...
Former names
CVG CONTROLLED INC
SEC CIK
Corporate docs
Subsidiaries
Edwards Lifesciences LLC • Edwards Lifesciences Services GmbH • Edwards Lifesciences (U.S.) Inc. • Edwards Lifesciences (Japan) Limited ...
IRS number
364316614
EW stock data
Latest filings (excl ownership)
8-K
Edwards Lifesciences Reports Second Quarter Results
24 Jul 24
8-K
Regulation FD Disclosure
15 Jul 24
8-K
Departure of Directors or Certain Officers
10 Jul 24
8-K
Departure of Directors or Certain Officers
17 Jun 24
8-K
Agreement strengthens Edwards’ strategy to advance structural heart innovation
3 Jun 24
SD
Conflict minerals disclosure
30 May 24
8-K
Submission of Matters to a Vote of Security Holders
8 May 24
10-Q
2024 Q1
Quarterly report
29 Apr 24
8-K
Edwards Lifesciences Reports First Quarter Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Mar 24
Transcripts
EW
Earnings call transcript
2024 Q1
25 Apr 24
EW
Earnings call transcript
2023 Q4
6 Feb 24
EW
Earnings call transcript
2023 Q3
25 Oct 23
EW
Earnings call transcript
2023 Q2
26 Jul 23
EW
Earnings call transcript
2023 Q1
26 Apr 23
EW
Earnings call transcript
2022 Q4
31 Jan 23
EW
Earnings call transcript
2022 Q3
28 Oct 22
EW
Earnings call transcript
2022 Q2
29 Jul 22
EW
Earnings call transcript
2022 Q1
27 Apr 22
EW
Earnings call transcript
2021 Q4
27 Jan 22
Latest ownership filings
4
Daniel J. Lippis
11 Jul 24
144
Notice of proposed sale of securities
11 Jul 24
4
DONALD E BOBO JR
10 Jul 24
4
David T Feinberg
10 Jul 24
3
David T Feinberg
10 Jul 24
4
Catherine M. Szyman
8 Jul 24
4
Daniel J. Lippis
8 Jul 24
4
Jean-Luc M Lemercier
8 Jul 24
3
Andrew M. Dahl
1 Jul 24
4
Daniel J. Lippis
20 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.23 bn | 1.23 bn | 1.23 bn | 1.23 bn | 1.23 bn | 1.23 bn |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | (no burn) | 17.83 mm | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | n/a | 68.95 mm | n/a |
Cash remaining | n/a | n/a | n/a | n/a | 1.16 bn | n/a |
Runway (months of cash) | n/a | n/a | n/a | n/a | 65.0 | n/a |
Institutional ownership, Q1 2024
77.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1199 |
Opened positions | 315 |
Closed positions | 128 |
Increased positions | 348 |
Reduced positions | 348 |
13F shares | Current |
---|---|
Total value | 42.17 tn |
Total shares | 468.68 mm |
Total puts | 3.28 mm |
Total calls | 3.85 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 52.96 mm | $5.06 tn |
BLK Blackrock | 52.42 mm | $5.01 tn |
STT State Street | 26.78 mm | $2.56 tn |
BK Bank Of New York Mellon | 18.97 mm | $1.81 tn |
Brown Advisory | 16.64 mm | $1.59 tn |
Alliancebernstein | 16.41 mm | $1.57 tn |
Wellington Management | 15.55 mm | $1.49 tn |
Geode Capital Management | 13.09 mm | $1.25 tn |
JPM JPMorgan Chase & Co. | 9.57 mm | $914.88 bn |
FMR | 8.24 mm | $787.37 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jul 24 | Daniel J. Lippis | Common Stock | Sell | Dispose S | No | Yes | 94.18 | 500 | 47.09 k | 23,189.065 |
11 Jul 24 | Daniel J. Lippis | Common Stock | Option exercise | Acquire M | No | Yes | 45.2767 | 500 | 22.64 k | 23,689.065 |
11 Jul 24 | Daniel J. Lippis | Employee Stock Option (Right to Acquire) Common Stock | Option exercise | Dispose M | No | No | 45.2767 | 500 | 22.64 k | 4,530 |
10 Jul 24 | Bobo Donald E JR | Common Stock | Sell | Dispose S | No | Yes | 93.2948 | 5,000 | 466.47 k | 46,935.718 |
10 Jul 24 | Bobo Donald E JR | Common Stock | Option exercise | Acquire M | No | Yes | 45.2767 | 5,000 | 226.38 k | 51,935.718 |
10 Jul 24 | Bobo Donald E JR | Employee Stock Option (Right to Acquire) Common Stock | Option exercise | Dispose M | No | No | 45.2767 | 5,000 | 226.38 k | 55,500 |
10 Jul 24 | David T Feinberg | Common Stock | Grant | Acquire A | No | No | 0 | 2,308 | 0.00 | 2,308 |
7 Jul 24 | Szyman Catherine M. | Common Stock | Payment of exercise | Dispose F | No | No | 92.32 | 258 | 23.82 k | 75,907.437 |
News
Market Whales and Their Recent Bets on Edwards Lifesciences Options
26 Jul 24
Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
26 Jul 24
Goldman Sachs Maintains Buy on Edwards Lifesciences, Lowers Price Target to $91
26 Jul 24
S&P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In 'Fear' Zone
26 Jul 24
TD Cowen Downgrades Edwards Lifesciences to Hold, Lowers Price Target to $70
25 Jul 24
Press releases
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
24 Jul 24
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024
17 Jul 24
Edwards Lifesciences to Acquire Innovalve
15 Jul 24
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
5 Jun 24
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
3 Jun 24